ARCA biopharma (NASDAQ:ABIO) Coverage Initiated at StockNews.com

Analysts at StockNews.com assumed coverage on shares of ARCA biopharma (NASDAQ:ABIO) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

ARCA biopharma Stock Performance

ARCA biopharma has a 1-year low of $1.56 and a 1-year high of $4.49. The company’s fifty day moving average is $394.93 and its 200-day moving average is $406.31. The company has a market capitalization of $34.82 million, a price-to-earnings ratio of -5.71 and a beta of 0.91.

ARCA biopharma (NASDAQ:ABIO) last issued its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($25.92) earnings per share (EPS) for the quarter.

Insider Buying and Selling at ARCA biopharma

In related news, major shareholder Henderson Group Plc Janus acquired 1,318 shares of the firm’s stock in a transaction on Wednesday, July 24th. The shares were bought at an average cost of $460.80 per share, with a total value of $607,334.40. Following the completion of the acquisition, the insider now owns 14,452 shares of the company’s stock, valued at $6,659,481.60. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have purchased 3,421 shares of company stock valued at $1,666,176. 30.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Cable Car Capital LLC bought a new position in ARCA biopharma in the 4th quarter worth approximately $6,801,000. Cubist Systematic Strategies LLC bought a new stake in shares of ARCA biopharma during the 2nd quarter valued at $106,000. Renaissance Technologies LLC raised its position in shares of ARCA biopharma by 11.3% during the 2nd quarter. Renaissance Technologies LLC now owns 73,099 shares of the biopharmaceutical company’s stock valued at $280,000 after acquiring an additional 7,400 shares during the last quarter. Perceptive Advisors LLC bought a new stake in shares of ARCA biopharma during the 2nd quarter valued at $59,395,000. Finally, Driehaus Capital Management LLC bought a new stake in shares of ARCA biopharma during the 2nd quarter valued at $14,731,000. Institutional investors own 56.44% of the company’s stock.

About ARCA biopharma

ARCA biopharma, Inc, a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure.